Author/Authors :
Fatehi, Farzad tehran university of medical sciences tums - Shariati Hospital - Department of Neurology, تهران, ايران , Nafissi, Shahriar tehran university of medical sciences tums - Shariati Hospital - Department of Neurology, تهران, ايران , Basiri, Keivan isfahan university of medical sciences, ايران , Amiri, Mostafa tehran university of medical sciences tums - Shariati Hospital - Department of Neurology, تهران, ايران , Soltanzadeh, Akbar tehran university of medical sciences tums - Shariati Hospital - Department of Neurology, تهران, ايران
Abstract :
Various forms of neuropathy are seen diabetic patients; chronic inflammatory demyelinating polyneuropathy (CIDP) seems not to be infrequent neuropathy in patients suffering from diabetes and it seems to be more common than in the general population; on the contrary, some authorities do not support pathogenetic association between diabetes mellitus (DM) and CIDP. Also, there are some controversies on the subject of CIDP treatment in diabetic patients. Some studies showed that patients with CIDP‑DM considerably had recovered following treatment with immunotherapeutic modalities like (Intravenous immunoglobulin) IVIG and conversely, some else have argued against the prescription of IVIG in this group and recommend treatment with corticosteroids and provided that resistant, rituximab may be beneficial. The main limitation in most studies is the inadequate number of cases and as a result, problematic decision making in treatment. This article represents an inclusive review of diabetic CIDP presentation and treatment.
Keywords :
diabetes mellitus , chronic inflammatory demyelination polyneuropathy , intravenous immunoglobulin , treatment